

**P1416**

**Paper Poster Session**

**Hepatitis C management focussing on new antivirals**

**Detection of Q80K polymorphism using real-time PCR and next-generation sequencing prior to simeprevir therapy in HCV**

Silvia Galli<sup>1</sup>, Danila Dal Monte<sup>1</sup>, Annarita Barbieri<sup>1</sup>, Maria Vittoria Tamburini<sup>1</sup>, Monica Compri<sup>1</sup>, Agnese Denicolò<sup>1</sup>, Maria Grazia Meliconi<sup>1</sup>, Giuliano Furlini<sup>1</sup>

<sup>1</sup>*Sant'Orsola-Malpighi Hospital, Microbiology Unit, Bologna, Italy*

**Background:** Hepatitis C Virus infection is the leading cause of chronic liver disease and hepatocellular carcinoma in Western Countries. Therapy improvements have been accomplished in last years: the treatment with direct-acting antiviral agents (DAAs) is associated with a high rate of sustained virological response. Simeprevir is a novel NS3/4 viral protease inhibitor that has been recently approved for the treatment of HCV infection in a multidrug therapeutic approach. However the presence of natural variants, mainly Q80K polymorphism in HCV genotype 1a, is associated with resistance to simeprevir. Thus, a screening for Q80K mutation is highly recommended prior to drug administration. The aim of our study is to provide the Q80K prevalence at baseline in a group of 126 patients eligible for DAAs treatment at Sant'Orsola-Malpighi Hospital, Bologna, Italy, using Real Time Polymerase Chain Reaction (RT-PCR) and direct sequencing.

**Material/methods:** Between April and July 2015, we enrolled 126 patients attending to Hepatology Unit with presumptive HCV genotype 1a infection, in order to detect Q80K polymorphism before simeprevir treatment. RNA extraction from plasma samples has been performed with ROBOT EZ1 (Qiagen®), and the extracted nucleic acid has been amplified by Versant® kPCR (Siemens Healthcare Diagnostics) using a Q80K Polymorphism Kit (Clonit srl). Samples showing no RT-PCR amplification were analyzed with a different protocol: after RNA extraction, the synthesized HCV cDNA was amplified using a home-made nested PCR and subsequently sequenced using GS Junior 454 (Roche®).

**Results:** Polymorphism analysis obtained with RT-PCR detected 84 wild type strains (66.6%) and 28 strains with Q80K mutation (22.2%). Next Generation Sequencing (NGS) was performed on the 14 unamplified samples: three of them had a different genotype from 1a, one showed an undetectable viral load, nine were HCV wild type and only one carried the Q80K polymorphism.

**Conclusions:** Overall, in our study, Q80K mutation occurred in 29 out of 126 subjects (23%). The polymorphism has a substantially high prevalence in our cohort and this highlights the value of screening HCV patients before subjecting them to the simeprevir therapy. Both methods showed a good performance, and our data could suggest a diagnostic algorithm: a first step based on the RT-PCR, a rapid and completely automatic platform, keeping NGS as a second level test for those samples that show an unexpected result.